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Objectives Ameloblastoma is an odontogenic neoplasm with locally aggressive behavior. Fas and FasL play important 
roles in apoptotic pathways. The aim of this study was to determine the possible role of expression of apoptotic 
pathways (Fas and FasL) in human ameloblastoma and the relationship of apoptosis with the clinical biological 
characteristics of ameloblastoma. 
Methods In this descriptive retrospective study, we investigated the anti-Fas and anti-FasL antibody expression in 11 
dental follicles and 56 ameloblastoma specimens (35 conventional, 15 unicystic and 6 ameloblastic carcinoma samples) 
by immunohistochemical (IHC) staining and polymerase chain reaction (PCR). The percentage of positive cells was 
calculated by using the Mann-Whitney U test and Kruskal-Wallis test. 
Results The rate of expression of markers was significantly lower in dental follicles than all subtypes of ameloblastoma 
(P=0.01 for Fas, and P=0.0001 for FasL). The FasL proportional score was significantly higher in conventional 
ameloblastoma than in unicystic ameloblastoma and ameloblastic carcinoma (P=0.003). There was no significant 
relationship between the type of ameloblastoma and expression of Fas. 
Conclusion This study shows that the process of apoptosis in ameloblastomais a sign of behavioral change in 
odontogenic epithelial cells especially in conventional ameloblastoma and that the apoptotic factors may not play an 
effective role in the malignancy of ameloblastoma. 




The odontogenic epithelium is responsible for tooth 
development in physiological conditions. It can also give 
rise to odontogenic cysts and tumors.
1, 2
 Ameloblastoma is 
one of the most commonly encountered benign odontogenic 
epithelial tumors. It is clinically characterized as a benign 
but locally invasive tumor with a high recurrence rate.
3
 
Ameloblastic carcinoma is a type of ameloblastoma with 
cytological features of malignancy at the primary or 
metastatic site.
4
 Apoptosis, also known as programed or 
physiological cell death, plays diverse roles in 
embryogenesis and normal homeostasis as well as in 
oncogenesis.
5,6
 Mutations affecting genes, viruses, 
radiation, growth factors, heat shock proteins, and Fas 
antigen [also known as Fas, FasR, apoptosis antigen 1 
(APO-1 or APT), cluster of differentiation 95 (CD95) or 
tumor necrosis factor receptor superfamily member 6 
(TNFRSF6)] play important roles in apoptosis.
7, 8, 9
 Among 
the various apoptotic pathways, the Fas/FasL system plays a 
key role. The Fas ligand (FasL or CD95L), a cell-surface 
molecule belonging to the tumor necrosis factor family, 
binds to its receptor Fas. This triggers a series of 
intracellular events leading to the activation of caspases that 




Altered expression of Fas and/or FasL has been detected in 
many neoplasms, which implies that Fas/FasL-induced 
apoptosis may play a role in the development and 
progression of some tumors.
12, 13
 Down-regulation of Fas 
and up-regulation of FasL were observed in neoplastic 
ameloblastoma as matched with benign ameloblastoma, 
signifying the release from death of cells attacked by the 
immune cells. Basal cell ameloblastomahas shown low 
expression and desmoplastic ameloblastoma has shown 
high expression of Fas and caspase-3.
14, 15
 The expression of 
FasL and Fas are closely associated with squamous 
metaplasia and granular transformation of the tumor cells, 
suggesting that apoptosis induced by FasL may play a role 




Evidence shows that apoptotic pathways may play an 
important role in odontogenesis or cytodifferentiation of 
odontogenic epithelium. Considering the high incidence 
rate of ameloblastoma, it seems that prompt differentiation 
between subtypes of ameloblastoma based on their growth 
rate, invasion and malignant transformation potential is 
warranted. In the present study, the immunohistochemical 
(IHC) expression of Fas and FasL was examined in dental 
follicles, conventional ameloblastoma, unicystic 
ameloblastoma and ameloblastic carcinoma, and the 
correlation between them was analyzed. 
  
Methods and Materials 
This study was performed in the Oral and Maxillofacial 
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Pathology Department of School of Dentistry, Shahid 
Beheshti University of Medical Sciences. This descriptive 
retrospective study was conducted on 11 dental follicles and 
56 ameloblastoma specimens (35 conventional, 15 unicystic 
and 6 ameloblastic carcinoma samples). Formalin-fixed 
paraffin-embedded specimens of 31 males and 25 females 
with a mean age of 34.2 years (range 12-72 years) were 
evaluated. Four specimens were from the maxilla (7.1%) 
and 52 specimens were from the mandible (92.9%); 
35specimens were conventional ameloblastoma, 15 
specimens were unicystic ameloblastoma and 6 specimens 
were ameloblastic carcinoma. 
IHC staining: 
Serial sections (4-μm thick) were made from the tissue 
blocks and processed for IHC examination. For 
immunohistochemical staining, we used the labeled 
streptavidin-biotin method with anti-Fas and FasL 
antibodies. The tissue sections were deparaffinized and 
dehydrated with gradient alcohol (96%); then, the tissue 
sections were immersed in buffering sodium citrate (pH=6) 
for antigen retrieval and were heated in a microwave. The 
Fas-L marker was heated for 15 minutes (five minutes with 
800W, 10 minutes with 600W[600 watt]) and the Fas 
marker was heated for 30 minutes (five minutes with 800W  
10 minutes with 600W and 15 minutes with 350W). After 
cooling at room temperature, the specimens were rinsed 
thoroughly with phosphate buffered saline (PBS, pH= 7.6) 
for five minutes, immersed in hydrogen peroxide for 10 
minutes and finally rinsed with distilled water and PBS. 
After this protocol, the sections were stained with primary 
antibodies. The applied antibodies were Fasmonoclonal 
antibody (1:50 dilution, CloneGM 30,1 mL, Novocastra, 
UK) and Fas-L monoclonal antibody (1:50 dilution, Clone 
5D1, 1mL, Novocastra, UK). The Fas and Fas-L specimens 
were incubated at room temperature for 90 and 60 minutes, 
respectively. Next, the sections were incubated with 
secondary antibodies for 30 minutes. We used 
diaminobenzeneaschromogen and hematoxylin for 
background staining. For negative control studies of the 
antibodies, the serial sections were treated with PBS and 
normal IgG instead of the secondary antibodies and for the 
positive control, the colon epithelium was used. 
Microscopic analysis: 
The IHC staining was membranous/ cytoplasmic. For 
evaluation of Fas and Fas-L expressions, we used the total 
score (total score=intensity score+ proportional score). In 
this study, the intensity score was referred to the intensity of 
cell staining (0= no staining, 1= weak staining, 2= moderate 
staining, and 3= severe staining). The proportional score 
was referred to the proportion of positively stained cells (0= 
no staining, 1≥ 1%, 2=1%-10%, 3=10%-33.3%, 4=33.3%-
66.6 and 5=Up to 66.6%) based on the Dako catalogue. All 
specimens were analyzed by two maxillofacial pathologists 
at different times. 
Polymerase chain reaction (PCR): 
For dental follicle and different types of ameloblastoma 
specimens, DNA extraction was performed and primers 
(Fas, FasL) (CinnaGen company, Iran) were prepared and 
processed as follows (Figure 1): 
 





The total score was calculated for ameloblastoma 
specimens and dental follicles. The Mann-Whitney U test 
and the Kruskal-Wallis test were used for data analysis via 




Based on the proportional score, Fas staining was negative 
for dental follicles and mildly positive for ameloblastoma 
(Table 1, Figures 2 and 3). 
Table 1- Fas staining based on the proportional score in 
ameloblastoma and dental follicle 
Proportional 
score 
0 1 2 Total 
Ameloblastoma 31(55.4%) 20(35.7%) 5(8.9%) 56 (100%) 
Dental follicle 11 (100%) 0(0%) 0 (0%) 11(100%) 
Total 42(62.7%) 20(29.9%) 5(7.5%) 67 (100%) 
 
Figure 2- Low expression of Fas in dental follicle at x100 




Apoptotic biomarkers, ameloblastoma and dental follicle              Fatemeh Mashhadiabbas, et al.                                                                                                                                                                                                                       
 
 
71  Journal Dental School; Vol 38, No.2, Spring 2020; 69-73  
Figure 3- Low expression of Fas in ameloblastoma at x100 
magnification (IHC staining) 
In general, 54.5% of dental follicle samples and 96.3% of 
ameloblastoma samples were highly stained for FasL 
markers based on the proportional score (Table 2, Figure 4). 
Based on the intensity score, Fas staining was negative in 
dental follicle samples and positive in 44.6% of 
ameloblastoma samples (Table 3). 
Overall, 62.5% of ameloblastoma samples were highly 
stained for FasL marker and 81.8% of dental follicle 
samples were mildly stained for this marker based on the 
intensity scores (Table 4). 
In comparison between dental follicle and types of 
ameloblastoma, the intensity score for FasL was lower in 
dental follicle than in ameloblastoma samples (P=0.0001). 
Rate of expressions based on the total score was lower in 
dental follicle than in ameloblastoma, and these differences 
were statistically significant (P=0.01 for Fas and P=0.0001 
for FasL). The FasL proportional score was higher in 
conventional ameloblastoma than in unicystic and 
ameloblastic carcinoma (Table 5), and this difference was 
statistically significant (P=0.003). There was no significant 
relationship between the types of ameloblastoma and 
expression of Fas marker (P=0.28, Table 6). 
 
Table 2- FasL staining based on the proportional score in ameloblastoma and dental follicle 
 0 1 2 3 4 5 Total 
Ameloblastoma 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2(3.6%) 54(96.4%) 56(100%) 
Dental follicle 1(9.1%) 1(9.1%) 1(9.1%) 1(9.1%) 1(9.1%) 6(54.5%) 11(100%) 
Total 1(1.5%) 1(1.5%) 1(1.5%) 1(1.5%) 3(5.4%) 60(89.6%) 67(100%) 
 
 
Figure 4- High expression of FasL in conventional ameloblastomaat x100magnification (IHC staining) 
Table 3- Fas staining based on the intensity score in ameloblastoma and dental follicle 
 Without staining Mild Moderate Severe Total 
Ameloblastoma 31(55.4%) 6(10.7%) 5(8.9%) 14(25%) 56(100%) 
Dental follicle 11(100%) 0 (0%) 0 (0%) 0 (0%) 11(100%) 
Total 42(62.7%) 6(9%) 5(7.5%) 14(20.9%) 67(100%) 
 
Table 4- Fas staining based on the intensity score in ameloblastoma and dental follicle 
 Negative Mild Moderate Severe Total 
Ameloblastoma 0 (0%) 3(5.4%) 18(32.1%) 35(62.5%) 56(100%) 
Dental follicle 1(9.1%) 9(81.8%) 1(9.1%) 0 (0%) 11(100%) 
Total 1(1.5%) 12(17.9%) 19(28.4%) 35(52.2%) 67(100%) 
 
Table 5- FasL staining based on the proportional score in subtypes of  ameloblastoma 
Proportional score 4 5 Total 
Conventional ameloblastoma 0(0%) 35(100%) 35(100%) 
Unicystic ameloblastoma 1(6.7%) 14(93.3%) 15(100%) 
Ameloblastic carcinoma 1(16.7%) 5(83.3%) 6(100%) 




The comparison between different subtypes of 
ameloblastoma showed that in ameloblastic carcinoma, the 
proportional score of Fas was similar to that of dental 
follicle (P=0.001); this score was 83.3% for FasL, which 
was lower than that of conventional ameloblastoma (100%) 
and unicystic ameloblastoma (93.3%). 
The purpose of the PCR method was to detect single-
nucleotide polymorphisms at -670 of Fas gene promoter. 
Table 6-Fas staining based on the proportional score in subtypes of ameloblastoma 
Proportional score 0 1 2 Total 
Conventional ameloblastoma 20(57.1%) 13(37.1%) 2(5.8%) 35(100%) 
Unicystic ameloblastoma 7(46.7%) 6(40%) 2(13.3%) 15(100%) 
Ameloblastic carcinoma 4(66.6%) 1(16.7%) 1(16.7%) 6(100%) 
Total 31(55.4%) 20(35.7%) 5(8.9%) 56(100%) 
Original Article 
Apoptotic biomarkers, ameloblastoma and dental follicle                        Fatemeh Mashhadiabbas, et al.                                                                    
 
Journal Dental School; Vol 38, No.2, Spring 2020; 69-73  72  
Due to the use of paraffin samples in PCR, the PCR steps 
were repeated but no results were obtained. 
Discussion 
Ameloblastoma is among the most commonly encountered 
benign odontogenic epithelial tumors. It is clinically 
characterized as a benign but locally invasive tumor with a 
high recurrence rate.
3
 Based on its clinical and radiographic 
features, ameloblastoma is classified into three general 
subtypes of multicystic (75-86%), unicystic (13-21%) and 
peripheral (1-4%).
17
 Apoptosis, also known as programed or 
physiological cell death, may be induced by mutations 
affecting genes, viruses, radiation, growth factors, heat 
shock proteins, and Fas antigen.
5-9 
The Fas/FasL system was first thought to play a role in the 
immune system
18
; however, the expression of Fas and FasL 
has been detected in a variety of tissues, suggesting that the 
Fas/FasL system is implicated in apoptotic cell death during 
the physiological cell turnover.
12
 In the current study, 
immune reactivity of Fas and FasL was detected in 
ameloblastoma subtypes and in dental follicle. 
Mutations have been reported in the Fas gene and single 
nucleotide pleomorphism in the promoter region of the Fas 
gene. Mutations have also been reported in some tumors.
19
 
Also, tumor suppressor and anti-apoptotic pathways have 
been implicated in ameloblastoma pathogenesis. IHC 
studies have shown the expression of p53 and Mouse 
Double Minute 2 in the majority of ameloblastoma cases.
20
 
A recent study found some proteins related to apoptosis 
such as Bcl-2, Fas, FasL and caspase 3, which play major 
roles in proliferation of cells in dental follicle, odontogenic 
keratocyst, and ameloblastoma.
21 
Recently, down-regulation of Fas and up-regulation of FasL 
were detected in many human neoplasms, suggesting that 
neoplastic cells might defend against T-lymphocytes or 
other effector cells of the immune system.
22 
In the current 
study, Fas expression was slightly lower than Fas-L 
expression in ameloblastoma samples. None of the dental 
follicle samples expressed Fas marker, but FasL marker was 
positive in dental follicle samples. However, a previous 
study demonstrated the expression of both Fas and its 
ligand in dental follicles and suggested a relationship 
between the Fas/FasL system and tooth development.
23, 24 
This difference between the two studies may be due to IHC 
staining methods. Another study (Jain et al), similar to the 
present study, showed lower expression of Fas in 
ameloblastoma samples. 
25 
The expression of Fas and FasL 
in various patterns in tooth buds and benign and malignant 
ameloblastoma has also been reported.
26
 But, compared 
with tooth buds, level of expression of Fas was lower in 
ameloblastoma; whereas, FasL had similar expression in 
tooth buds and ameloblastoma
23, 24
 similar to our findings. 
A previous study detected the expression of Bcl-2 and Bcl-x 
in ameloblastoma.
11
 It has been proven that Bcl-2 and Bcl-x 
proteins inhibit the Fas-mediated apoptotic pathway.
19
 
These findings suggest that the Fas/ FasL system might be 
suppressed by the Bcl-2 family of proteins in 
ameloblastoma.
21, 27 
For the comparison of  results of PCR, 
we searched MeSH, PubMed and Google Scholar but no 
similar research was found. In our study, due to the use of 
paraffin samples in PCR, the PCR steps were repeated but 
no results were obtained. 
The statistical analysis in the current study showed that the 
expression of Fas and FasL markers in ameloblastoma was 
significantly higher than that in dental follicle samples, but 
their expressions in subtypes of ameloblastoma were the 
same, except for Fas-L marker, which showed significantly 
higher expression in conventional ameloblastoma versus the 
unicystic ameloblastoma and ameloblastic carcinoma. This 
finding shows that the Fas-FasL system does not affect the 
behavior of ameloblastoma subtypes. The comparison 
between different subtypes of ameloblastoma revealed that 
in ameloblastic carcinoma, the proportional score of Fas is 
similar to that of the dental follicle, and this score for FasL 
was 83.3% which was lower than that of conventional 




This study indicated that the process of apoptosis in 
ameloblastoma is a sign of behavioral changes in 
odontogenic epithelial cells especially in conventional 
ameloblastoma and the apoptotic factors may not play an 
effective role in the malignancy of ameloblastoma. 
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